These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34296214)

  • 1. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
    Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
    Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
    Negi A; Voisin-Chiret AS
    Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity.
    He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D
    Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.
    Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
    Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
    Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
    ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X
    Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G
    Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2-BCL-X
    Chang M; Gao F; Chen J; Gnawali G; Wang W
    Acta Mater Med; 2022 Jul; 1(3):333-342. PubMed ID: 36910255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Novel BCL-X
    Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
    J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
    Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M
    Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective BCL-X
    Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D
    Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BCL-XL in fibrolamellar hepatocellular carcinoma.
    Shebl B; Ng D; Lalazar G; Rosemore C; Finkelstein TM; Migler RD; Zheng G; Zhang P; Jiang CS; Qureshi A; Vaughan R; Yarchoan M; de Jong YP; Rice CM; Coffino P; Ortiz MV; Zhou D; Simon SM
    JCI Insight; 2022 Sep; 7(17):. PubMed ID: 36073545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
    Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
    Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-x
    Zhang X; Tao Y; Xu Z; Jiang B; Yang X; Huang T; Tan W
    Biochem Pharmacol; 2024 Dec; 230(Pt 1):116542. PubMed ID: 39284500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.